OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.12 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About CytoDyn Stock (OTCMKTS:CYDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.12▼$0.1250-Day Range$0.12▼$0.1752-Week Range$0.11▼$0.42Volume1.86 million shsAverage Volume2.83 million shsMarket Capitalization$141.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More… My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO CytoDyn Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks8th Percentile Overall ScoreCYDY MarketRank™: CytoDyn scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.36% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoDyn has recently increased by 25.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.36% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoDyn has recently increased by 25.78%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentCytoDyn has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CytoDyn this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of CytoDyn is held by insiders.Percentage Held by InstitutionsOnly 5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Stock News HeadlinesCytoDyn Announces FDA Clearance of Its Phase II Oncology TrialNovember 4, 2024 | globenewswire.comCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesOctober 30, 2024 | globenewswire.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 21, 2024 | Crypto 101 Media (Ad)CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentOctober 8, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | globenewswire.comCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology TrialOctober 4, 2024 | globenewswire.comCytoDyn Announces Preliminary Findings in Study with SMC LaboratoriesSeptember 24, 2024 | globenewswire.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.1950 at the beginning of the year. Since then, CYDY shares have decreased by 40.4% and is now trading at $0.1163. View the best growth stocks for 2024 here. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) posted its quarterly earnings results on Tuesday, October, 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings10/15/2024Today11/21/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,840,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-129.84% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$270,000.00 Price / Sales525.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-1.06Miscellaneous Outstanding Shares1,219,350,000Free Float1,212,763,000Market Cap$141.81 million OptionableNot Optionable Beta0.17 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.